This webinar provides a debate on HF device therapy options that are now available for patients. While HF patients are treated aggressively with GDMT, many remain symptomatic and struggle with their everyday activities. This program will involve a faculty that will each present a technology and review the clinical evidence supporting the device, indications for use, screening and identifying patients, the procedure overview, and the benefits for patients. Devices that will be covered in the debate include: Cardiac Resynchronization Therapy (CRT), Cardiac Contractility Modulation (CCM®), and Barostimulator Therapy (BAT). The structure of this session will allow for rebuttal as well as an all faculty Q & A.
October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.